Monte Rosa Therapeutics (GLUE) Restructuring Costs (2024 - 2026)

Monte Rosa Therapeutics' Restructuring Costs history runs 3 years deep, the most recent figure standing at $10.1 million for Q1 2026.

• In Q1 2026, Restructuring Costs rose 22.89% year-over-year to $10.1 million; the TTM figure through Mar 2026 stood at $35.7 million (up 15.13% YoY), while the FY2025 annual figure was $33.9 million, up 14.3% from the prior year.
• Restructuring Costs for Q1 2026 stood at $10.1 million, up from $9.2 million in the prior quarter.
• The five-year high for Restructuring Costs was $10.1 million in Q1 2026, with the low at $6.8 million in Q1 2024.
• The 3-year median for Restructuring Costs is $7.8 million (2025), against an average of $8.2 million.
• The sharpest annual moves came in 2025 and 2026: Restructuring Costs advanced 2.99% in 2025, then climbed 22.89% in 2026.
• Monte Rosa Therapeutics' Restructuring Costs stood at $7.7 million in 2024, then grew by 18.95% to $9.2 million in 2025, then advanced by 9.74% to $10.1 million in 2026.
• Business Quant data shows GLUE's Restructuring Costs at $10.1 million in Q1 2026, $9.2 million in Q4 2025, and $8.6 million in Q3 2025.